Clinical Trials in CRS and HIPEC: Ongoing Trials and Future Directives

  • William F. Morano
  • Wilbur B. Bowne
  • Jesus Esquivel


Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have gained momentum as a viable treatment option for primary or recurrent malignancies with peritoneal metastasis (PM). Despite significant progress over the last 30 years, this field has lacked in high-quality randomized, controlled trials, with most data supporting the use of CRS and HIPEC coming from smaller retrospective and prospective trials. Ultimately, validation of treatment efficacy and outcomes will require large, collaborative, well-organized, outcomes-based studies. Thus far, the use of CRS and HIPEC in metastatic gastric, ovarian, pancreatic, and other gastrointestinal malignancies has spurred further development of a growing number of prospective clinical trials to study outcomes and survival benefit. This chapter summarizes some of the notable, completed clinical trials and current trials being conducted.


Peritoneal metastasis Hyperthermic intraperitoneal chemotherapy (HIPEC) Cytoreductive surgery (CRS) Peritoneal carcinomatosis Randomized controlled trials (RCT) 


  1. 1.
    Sugarbaker PH, Graves T, DeBruijn EA, et al. Early postoperative intraperitoneal chemotherapy as an adjuvant therapy to surgery for peritoneal carcinomatosis from gastrointestinal cancer: pharmacological studies. Cancer Res. 1990;50(18):5790–4.PubMedGoogle Scholar
  2. 2.
    Feldman AL, Libutti SK, Pingpank JF, et al. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol. 2003;21(24):4560–7.CrossRefPubMedGoogle Scholar
  3. 3.
    Network NCC. NCCN Guidelines Version 2.2016 Colon Cancer. Available from:
  4. 4.
    Knorr C, Reingruber B, Meyer T, et al. Peritoneal carcinomatosis of colorectal cancer: incidence, prognosis, and treatment modalities. Int J Colorectal Dis. 2004;19(3):181–7.CrossRefPubMedGoogle Scholar
  5. 5.
    Brodsky JT, Cohen AM. Peritoneal seeding following potentially curative resection of colonic carcinoma: implications for adjuvant therapy. Dis Colon Rectum. 1991;34(8):723–7.CrossRefPubMedGoogle Scholar
  6. 6.
    Glehen O, Kwiatkowski F, Sugarbaker PH, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol. 2004;22(16):3284–92.CrossRefPubMedGoogle Scholar
  7. 7.
    Verwaal VJ, van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21(20):3737–43.CrossRefPubMedGoogle Scholar
  8. 8.
    Sugarbaker PH, Schellinx ME, Chang D, et al. Peritoneal carcinomatosis from adenocarcinoma of the colon. World J Surg. 1996;20(5):585–91.CrossRefPubMedGoogle Scholar
  9. 9.
    Elias DM, Ouellette JF. Intraperitoneal chemohyperthermia: rationale, technique, indications, and results. Surg Oncol Clin N Am. 2001;10(4):915–33.PubMedGoogle Scholar
  10. 10.
    Bloemendaal ALA, Verwaal VJ, van Ruth S, et al. Conventional surgery and systemic chemotherapy for peritoneal carcinomatosis of colorectal origin: a prospective study. Eur J Surg Oncol. 2005;31(10):1145–51.CrossRefPubMedGoogle Scholar
  11. 11.
    Jayne DG, Fook S, Loi C, et al. Peritoneal carcinomatosis from colorectal cancer. Br J Surg. 2002;89(12):1545–50.CrossRefPubMedGoogle Scholar
  12. 12.
    Verwaal VJ, Bruin S, Boot H, et al. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol. 2008;15(9):2426–32.CrossRefPubMedGoogle Scholar
  13. 13.
    Glehen O, Mithieux F, Osinsky D, et al. Surgery combined with peritonectomy procedures and intraperitoneal chemohyperthermia in abdominal cancers with peritoneal carcinomatosis: a phase II study. J Clin Oncol. 2003;21(5):799–806.CrossRefPubMedGoogle Scholar
  14. 14.
    Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11–20.CrossRefPubMedGoogle Scholar
  15. 15.
    Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345(10):725–30.CrossRefPubMedGoogle Scholar
  16. 16.
    Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357(18):1810–20.CrossRefPubMedGoogle Scholar
  17. 17.
    Yonemura Y, Endou Y, Shinbo M, et al. Safety and efficacy of bidirectional chemotherapy for treatment of patients with peritoneal dissemination from gastric cancer: selection for cytoreductive surgery. J Surg Oncol. 2009;100(4):311–6.CrossRefPubMedGoogle Scholar
  18. 18.
    Yang XJ, Huang CQ, Mei LJ, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol. 2011;18(6):1575–81.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Sugarbaker PH. Management of peritoneal surface malignancy: the surgeon’s role. Langenbecks Arch Surg. 1999;384(6):576–87.CrossRefPubMedGoogle Scholar
  20. 20.
    Pölcher M, Zivanovic O, Chi D. Cytoreductive surgery for advanced ovarian cancer. Womens Health. 2014;10(2):179–90.Google Scholar
  21. 21.
    Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;534(1):34–43.CrossRefGoogle Scholar
  22. 22.
    Spilliotis J, Halkia E, Lianos E, et al. Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study. Ann Surg Oncol. 2015;22(5):1570–5.CrossRefGoogle Scholar
  23. 23.
    Kurman RJ, Shih IM. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer—shifting the paradigm. Hum Pathol. 2011;42(7):918–31.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004;22(1):23–30.CrossRefPubMedGoogle Scholar
  25. 25.
    Souglakos J, Kalykaki A, Vamvakas L, et al. Phase II trial of capecitabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatic colorectal cancer who progressed after oxaliplatin-based chemotherapy. Ann Oncol. 2007;18(2):305–10.CrossRefPubMedGoogle Scholar
  26. 26.
    Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205–13.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Zivanovic O, Abramian A, Kullmann M, et al. HIPEC ROC I: a phase I study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum-based chemotherapy in patients with platinum-sensitive recurrent epithelial ovarian cancer. Int J Cancer. 2014;136(3):699–708.PubMedGoogle Scholar
  28. 28.
    Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.CrossRefPubMedGoogle Scholar
  29. 29.
    Zhou L, Guan P, Sun L, et al. Health economic assessment for screening of gastric cancer in a high risk population in northeastern China. Chin J Cancer Res. 2011;23(1):21–4.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Beeharry MK, Liu WT, Yao XX, et al. A critical analysis of the cytoreductive surgery with hyperthermic intraperitoneal chemotherapy combo in the clinical management of advanced gastric cancer: an effective multimodality approach with scope for improvement. Transl Gastroenterol Hepatol. 2016;20(1):77.CrossRefGoogle Scholar
  31. 31.
    Lowe KA, Danese MD, Gleeson ML, et al. Racial and ethnic variability in the prevalence and incidence of comorbidities associated with gastric cancer in the United States. J Gastrointest Cancer. 2016;47(2):168–81.CrossRefPubMedGoogle Scholar
  32. 32.
    Beckert S, Löffler M, Meisner C, et al. Open-label pilot phase I/II study of hyperthermic intraperitoneal chemotherapy in addition to macroscopic complete resection (R0/R1) of pancreatic adenocarcinoma. J Peritoneum. 2016;1(s1):75.Google Scholar
  33. 33.
    Castellanos JA, Mechant NB. Intensity of follow-up after pancreatic cancer resection. Ann Surg Oncol. 2014;21(3):747–51.CrossRefPubMedGoogle Scholar
  34. 34.
    Tentes AA, Stamou K, Pallas N, et al. The effect of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) as an adjuvant in patients with resectable pancreatic cancer. Int J Hyperthermia. 2016;32(8):895–9.CrossRefPubMedGoogle Scholar
  35. 35.
    Tentes AA, Kyziridis D, Kakolyris S, et al. Preliminary results of hyperthermic intraperitoneal intraoperative chemotherapy as an adjuvant in resectable pancreatic cancer. Gastroenterol Res Pract. 2012;2012:506571.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Flatmark K, Guldvik IJ, Svensson H, et al. Immunotoxin targeting EpCAM effectively inhibits peritoneal tumor growth in experimental models of mucinous peritoneal surface malignancies. Int J Cancer. 2013;133(6):1497–506.CrossRefPubMedGoogle Scholar
  37. 37.
    Imano M, Okuno K. Treatment strategies for gastric cancer patients with peritoneal metastasis. Surg Today. 2014;44(3):399–404.CrossRefPubMedGoogle Scholar
  38. 38.
    Nummela P, Leinonen H, Järvinen P, et al. Expression of CEA, CA19-9, CA125, and EpCAM in pseudomyxoma peritonei. Hum Pathol. 2016;54:47–54.CrossRefPubMedGoogle Scholar
  39. 39.
    Andersson Y, Frøysnes IS, Larsen S, et al. Novel Intraperitoneal treatment for peritoneal metastases. Results from the immunotoxin in peritoneal carcinomatosis phase I trial. J Peritoneum. 2016;1(s1):27.Google Scholar
  40. 40.
    Pelz JO, Chua TC, Esquivel J, et al. Evaluation of best supportive care and systemic chemotherapy as treatment stratified according to the retrospective peritoneal surface disease severity score (PSDSS) for peritoneal carcinomatosis of colorectal origin. BMC Cancer. 2010;22:689.CrossRefGoogle Scholar
  41. 41.
    Yoon W, Alame A, Berri R. Peritoneal surface disease severity score as a predictor of resectability in the treatment of peritoneal surface malignancies. Am J Surg. 2014;207(3):403–7.CrossRefPubMedGoogle Scholar
  42. 42.
    Esquivel J, Lowy AM, Markman M, et al. The American Society of Peritoneal Surface Malignancies (ASPSM) multiinstitution evaluation of the Peritoneal Surface Disease Severity Score (PSDSS) in 1,013 patients with colorectal cancer with peritoneal carcinomatosis. Ann Surg Oncol. 2014;21(13):4195–201.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2018

Authors and Affiliations

  • William F. Morano
    • 1
  • Wilbur B. Bowne
    • 1
  • Jesus Esquivel
    • 2
  1. 1.Department of SurgeryDrexel University College of MedicinePhiladelphiaUSA
  2. 2.Department of SurgeryFrederick Memorial HospitalFrederickUSA

Personalised recommendations